Morgan Stanley downgraded Humana (HUM) to Underweight from Equal Weight with a price target of $174, down from $262. The firm says the company’s 2026 bid strategy and policy risk may slow its margin turnaround. The “disappointing” Medicare Advantage advance rate notice adds 2027 pressure for Humana and a new policy overhang across Medicare Advantage where the company is “disproportionately exposed,” the analyst tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.